Articles tagged with Prostate Cancer
A study by Dana-Farber Cancer Institute found that higher selenium levels can worsen prostate cancer outcomes for men carrying a specific SOD2 gene variant. Men with the highest selenium levels and this variant had a 40% lower risk of aggressive disease, while those with the lowest levels were twice as likely to develop it.
The Prostate Cancer Translational Research in Europe meeting showcased ongoing research efforts to identify biomarkers, genetic variants and new therapeutic options. Researchers discussed the importance of collaboration between clinicians and scientists to streamline current efforts and avoid duplication.
Sexual medicine experts focus on treating causes of sexual dysfunction beyond physical issues, exploring relationship dynamics and hormonal imbalance. New treatments and options for women and men are being developed to address complex sexual health needs.
Researchers used a combination of an immunotherapeutic agent called MDX-010 or ipilimumab with standardized hormone treatment and radiation therapy to treat advanced prostate cancer. The approach led to significant tumor shrinkage and cancer cell death, allowing surgery in two previously inoperable patients.
A recent study published in Cancer Prevention Research found that men with prostate cancer who consumed green tea demonstrated a significant reduction in serum markers predictive of disease progression. The study showed a 30% or greater reduction in levels of hepatocyte growth factor, vascular endothelial growth factor, and prostate-sp...
Researchers have developed a novel form of treatment using an alpha-particle emitting radiopeptide that targets and destroys cancer cells while sparing healthy tissue. The study found that this therapy was significantly more effective at tripling the survival rate of mice with recurrent prostate cancer compared to traditional treatments.
A new online decision tool allows prostate cancer patients to weigh their own preferences against medical data to personalize treatment plans. The tool considers multiple factors, including life expectancy and side effects, to guide treatment decisions.
A new risk assessment test, CAPRA, has been developed to predict long-term risks and pinpoint high-risk cases in prostate cancer. The test accurately predicted bone metastasis, prostate cancer-specific mortality, and all-cause mortality when localized prostate cancer is first diagnosed.
A recent study found that hormone therapy can alter prostate tumor properties, making them more aggressive and prone to metastasis. The treatment reduces male sex hormone production, but also increases levels of proteins enabling cancer cells to spread.
Researchers at Baylor College of Medicine discovered changes in 1,141 genes that induce the formation of new structures such as blood vessels and nerves in prostate cancer patients. These gene changes may explain why men with reactive stroma face a more aggressive disease.
A four-year UCLA study found significant impacts on quality of life for prostate cancer patients treated with radical prostatectomy, seed implants, or external beam radiation. The study developed 'probability plots' to predict when side effects will return to normal or if a patient will fully recover.
Two studies found that patients with cancer aged 65+ experience a significant decline in physical and mental health, leading to lower overall quality of life. The impact on HRQOL was quantified by analyzing changes in patients' well-being before and after diagnosis.
A new study has found that autoantibodies are not strongly associated with improved outcomes in melanoma patients treated with interferon. The CAPRA score was accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality at diagnosis of localized prostate cancer.
A new technique using gold nanoparticles could lead to an effective and affordable over-the-counter prostate cancer test kit. The test is designed to detect cancer-producing proteins related to prostate cancer, similar to the FDA-approved Prostate-Specific Antigen (PSA) test.
A diet rich in fruits and vegetables, such as tomatoes, cauliflower, and broccoli, may help prevent prostate cancer. Avoiding high-energy intake, excessive meat, dairy products, and calcium may also be beneficial.
A new blood test combined with PSA screening accurately detects prostate cancer over 90% of the time, reducing false-positives and potentially eliminating tens of thousands of unnecessary biopsies. The six-gene molecular diagnostic test improved specificity and sensitivity compared to PSA alone.
A recent study found that men with low oxygen levels in their prostate tumor are more likely to experience a return of prostate cancer after treatment. Researchers say this finding could lead to personalized treatment approaches, including combination therapies and non-invasive methods for detecting oxygen levels in tumors.
Research reveals that HGPIN carries a high predictive value for future diagnosis of prostate cancer, with a 41.8% risk identified in patients. The study recommends delaying first repeat biopsies at low PSA ranges but shorter intervals for intermediate and higher PSA ranges.
A phase I clinical trial of Zyflamend, a novel herbal therapy, demonstrates its safety and tolerability in men with high-grade prostatic intraepithelial neoplasia (HGPIN), a precursor to prostate cancer. The study confirms that Zyflamend is well-tolerated when administered orally for up to 18 months.
A new study found that younger men with advanced prostate cancer have a poorer prognosis than older men, despite having less aggressive tumors. The researchers suspect that young men may have biologically more aggressive forms of the disease.
Researchers found a protein, βarrestin2, that suppresses androgen receptor expression in prostate cancer cells, potentially halting disease progression. Increased levels of βarrestin2 may lead to improved staging and treatment of testosterone-fueled prostate cancer.
Researchers at University of Cincinnati have identified a new molecular pathway responsible for the rapid development of invasive prostate cancer tumors. The simultaneous inactivation of PTEN and Par-4 genes causes a synergistic effect leading to more aggressive tumors.
Researchers have developed a new 3-minute test that measures the level of citrate in fluid samples from the prostate gland to detect prostate cancer. The technique uses light energy and can provide an accurate way to screen and diagnose the disease, particularly in its early stages.
Researchers have identified a genetic marker associated with an earlier onset of prostate cancer in high-risk men. The Met160Val SNP is linked to a 2.5-fold increased risk of developing prostate cancer, and carriers are more likely to develop the disease earlier.
Researchers at Fox Chase Cancer Center found that low-oxygen regions in prostate tumors are associated with increased PSA levels, a marker of tumor recurrence. The study used a custom-built probe to monitor oxygen levels in tumors and non-cancerous muscle tissue before localized radiation therapy.
A recent study has identified four risk factors that can predict survival outcomes for men with metastatic prostate cancer, enabling doctors to choose more effective treatments. The researchers used data from over 1,000 patients and found that pain levels, anemia, cancer spread, and bone progression were key indicators of prognosis.
A new study from Henry Ford Hospital found that radical prostatectomy significantly increases long-term survival for men under 50 with prostate cancer. The procedure improved cancer-specific and overall survival rates compared to radiotherapy or watchful waiting, making it the recommended treatment option for younger patients.
Researchers identified BCL2, p53, and high microvessel density as molecular factors associated with increased risk of death from prostate cancer. Additionally, a study found that news reports often sensationalize medical research, potentially misleading the public about its relevance to human health.
A new study found that statins significantly lower PSA levels in men with prostate cancer, which may require adjusting the biopsy threshold for patients on statins. Statins have also been shown to lower prostate-specific antigen (PSA) levels in healthy men.
The Phase 3 IMPACT trial found that sipuleucel-T significantly prolonged overall survival by 4.1 months and improved three-year survival by 38 percent compared to placebo. This innovative immunotherapy reduced the risk of death by 22.5 percent.
The American Urological Association recommends individualized PSA testing for men 40 years or older with a life expectancy of at least 10 years. The test should be accompanied by a digital rectal exam to determine prostate cancer risk, which also considers family history and overall health.
The American Urological Association recommends PSA testing for men aged 40+, considering factors like family history and overall health. The new guidelines stress that prostate cancer is an individual decision, and the single standard should not apply to all men.
A new analysis finds that prostate cancer patients who undergo testosterone-lowering therapy are at higher risk of bone fractures and heart-related deaths. The study highlights the need for preventive measures and careful health scrutiny to mitigate these risks.
Researchers found a 72% reduction in risk for tumor inflammation among men taking statins, which may contribute to lower advanced prostate cancer incidence. Statin use could potentially control or prevent prostate cancer through anti-inflammatory effects.
Researchers found that a three-year combination therapy of vitamin E, selenium, and soy did not prevent the progression from HGPIN to prostate cancer. The study results show that 26.4% of participants developed invasive prostate cancer, regardless of baseline characteristics.
Researchers have established criteria for reclassifying prostate cancer risk over time, allowing for more tailored treatment approaches. Patients with slow-growing cancer can benefit from reduced therapy burden, while those with more aggressive disease receive definitive care.
A long-term clinical trial found that men who consumed pomegranate juice daily after treatment for localized prostate cancer experienced a significant increase in PSA doubling time and a decline in median PSA slope. This suggests that pomegranate juice may effectively slow the progression of post-treatment prostate cancer recurrence.
Researchers have identified two potential new targets in the fight against prostate cancer: 'cold shock' proteins that can be turned down through genetic techniques to weaken cancer cells, and higher bone density in men which may increase their risk of developing prostate cancer. Additionally, children with kidney stones are more likel...
A large Mayo Clinic cohort study found that statin use is associated with a reduced risk of prostate cancer, with non-statin users three times more likely to develop the condition. Statins may also protect against erectile dysfunction, particularly among older men, and prevent prostate enlargement.
MRI technology successfully identifies prostate cancer spread beyond the gland, helping doctors determine if surgery is necessary. The study reviewed 119 patients and found that MRI correctly identified 95% of T2 cases and 75% of T3 disease
Researchers developed a smart bomb-like drug delivery system that combines imaging with chemotherapy for prostate cancer treatment, showing promise in reducing tumor cells.
A study of 1,495 veterans found that those exposed to Agent Orange had a nearly 50% increased risk of prostate cancer recurrence and more aggressive cancers. This highlights the need for closer monitoring and timely intervention in these patients.
A University of Leicester team is developing a combined diagnosis/therapeutic strategy for prostate cancer using cutting-edge magnetic nanoparticles. The technology aims to identify and treat cancer cells at an early stage, reducing the need for surgical removal.
Researchers found racial disparities in cancer survival rates disappear when analyzing smaller geographic areas like neighborhoods. The study suggests that modifiable factors such as socioeconomic differences and access to medical care contribute to these disparities.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Researchers have developed a novel compound, MDV3100, which blocks the androgen receptor in CRPC cells, lowering PSA levels and reducing tumor growth.
A novel gene fusion, SLC45A3-ELK4, is highly expressed in prostate cancers and detectable in urine. This biomarker may help distinguish clinically significant from indolent disease.
Researchers have developed two new drugs, RD162 and MDV3100, that prevent male hormones from stimulating growth of prostate cancer cells. These compounds appear to work well even in prostate cells with heightened sensitivity to hormones, which makes them effective against drug-resistant prostate cancer.
A study identifies RNF6 as a protein that modifies androgen receptor activity in hormone-refractory prostate cancer. Inhibition of RNF6 shows promise as a new strategy for treating advanced prostate cancer, which no longer responds to traditional therapies.
Research shows that surgeons operating on prostate cancer patients face a steep learning curve when switching to laparoscopic surgery. Patients may be at increased risk of cancer recurrence if treated by inexperienced surgeons. To minimize this risk, specialist cancer centers with experienced surgeons are recommended.
Researchers at the University of Tokyo identified a novel biomarker to monitor acute kidney injury, while a study found that the unfolded protein response contributes to nerve cell death in Alzheimer's Disease. Additionally, a bacterial toxin disrupts intestinal epithelial barrier function, leading to systemic infection.
Researchers have found that sarcosine distinguishes between slow-growing and aggressive prostate cancers. The metabolomic analysis suggests that sarcosine is highly associated with tumour development and can predict the aggressiveness of tumors.
Human cytomegalovirus (HCMV) induces telomerase expression in both normal and malignant human cells, stimulating cell proliferation and immortalization. Additionally, a dietary supplement containing selenium, vitamin E, and beta-carotene reduces gastric cancer and overall mortality in individuals taking the supplements.
The SPCG-4 trial found that radical prostatectomy significantly reduces prostate cancer mortality and risk of metastases, with little to no increase in benefits over a 12-year follow-up. The study suggests that well-structured pre-treatment information, patient understanding, and support are crucial for managing prostate cancer.
Researchers are developing new classes of anti-androgen therapies, including MDV3100, abiraterone, and OGX-427, to treat castrate-resistant prostate cancer (CRPC). Angiogenesis inhibitors like bevacizumab target vascular endothelial growth factor (VEGF) to slow tumor growth and metastasis.
A major US study of 75,000 men found that annual prostate cancer screening led to more diagnoses but not fewer deaths. The study suggests that men with a short life expectancy may not need screening, and further research is needed to determine its benefits and harms.
The study found that PSA screening can reduce prostate cancer deaths by 20%, saving one life for every 1,408 men screened. The European Association of Urology's largest prostate cancer screening study provides robust evidence for the effectiveness of screening on prostate cancer mortality.
Researchers at the University of Nebraska Medical Center discovered that certain estrogen metabolites can damage DNA, initiating breast and prostate cancer. A new dietary supplement called Preventium combines natural compounds to block this mechanism, potentially reducing cancer risk.
A multi-center study recommends that men diagnosed with low-risk prostate cancer can safely choose observation over immediate treatment, closely monitored. This approach is associated with a low risk of metastatic spread and is not a total disregard for patients with prostate cancer.
Researchers found that study methods and definitions of lead time significantly impact estimates of prostate cancer screening's effectiveness. The study suggests a need for clear methodology to accurately interpret findings.
Daily folic acid supplements may increase prostate cancer risk by more than twice that of placebo. Baseline dietary folate intake and plasma levels showed a trend towards reduced risk but did not reach statistical significance. Researchers suggest large epidemiological studies using improved methods to study diet and cancer prevention.